Josh W. DiGiacomo

Josh W. DiGiacomo

Auto-generated profile, based on publicly available information

Josh W. DiGiacomo

Breast & Ovarian Cancer Program, Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2020 in Cancer Research
Verified
Journal Article
Closed access
PDF file
MMMahelet Mamo
Mahelet Mamo
IYI. Chae Ye
I. Chae Ye
JDJosh W. DiGiacomo
Josh W. DiGiacomo
JPJe Yeon Park
Je Yeon Park
BDBradley Downs
Bradley Downs
Daniele GilkesDaniele Gilkes
Daniele Gilkes
Intratumoral hypoxia occurs in 90% of solid tumors and is associated with a poor prognosis for patients. Cancer cells respond to hypoxic microenvironments by activating the transcription factors, hypoxia-inducible factor 1 (HIF1) and HIF2. Here, we studied the unique gene expression patterns of 31 different breast cancer cell lines exposed to hypoxic conditions. The EGFR, a member of the ErbB (avian erythroblastosis oncogene B) family of receptors that play a role in cell proliferation, invasion, metastasis, and apoptosis, was induced in seven of the 31 breast cancer cell lines by hypoxia. A functional hypoxia response element (HRE) was identified, which is activated upon HIF1 binding to intron 18 of the EGFR gene in cell lines in which EGFR was induced by hypoxia. CpG methylation of the EGFR HRE prevented induction under hypoxic conditions. The HRE of EGFR was methylated in normal breast tissue and some breast cancer cell lines, and could be reversed by treatment with DNA methyltransferase inhibitors. Induction of EGFR under hypoxia led to an increase in AKT, ERK, and Rb phosphorylation as well as increased levels of cyclin D1, A, B1, and E2F, and repression of p21 in an HIF1α-dependent manner, leading to cell proliferation and migration. Also, increased EGFR expression sensitized cells to EGFR inhibitors. Collectively, our data suggest that patients with hypoxic breast tumors and hypomethylated EGFR status may benefit from EGFR inhibitors currently used in the clinic. Significance: Hypoxia sensitizes breast cancer cells to EGFR inhibitors in an HIF1α- and a methylation-specific manner, suggesting patients with hypoxic tumors may benefit from EGFR inhibitors already available in the clinic. Graphical http://cancerres.aacrjournals.org/content/canres/80/22/4998/F1.large.jpg. Graphical Abstract

8 October 2020 in Molecular Cancer Research
Verified
Journal Article
Open access
PDF file
JDJosh W. DiGiacomo
Josh W. DiGiacomo
Ines GodetInes Godet
Ines Godet
MTMichael Trautmann-Rodriguez
Michael Trautmann-Rodriguez
Daniele GilkesDaniele Gilkes
Daniele Gilkes
The extracellular matrix (ECM) is often unaccounted for in studies that consider the stromal contribution to cancer cell signaling and response to treatment. To investigate the influence of a fibrotic microenvironment, we use fibroblast-derived ECM scaffolds as a cell culture platform. We uncover that estrogen receptor–positive (ER+) breast cancer cells cultured within ECM-scaffolds have an increase in ER signaling that occurs via an MAPK-dependent, but estrogen-independent manner. The ECM acts as a reservoir by binding, enriching, and presenting growth factors to adjacent epithelial cells. We identified FGF2 as a specific ECM-bound factor that drives ER signaling. ER+ cells cultured on ECM matrices have reduced sensitivity to ER-targeted therapies. The sensitivity to ER-targeted therapy can be restored by inhibiting FGF2–FGFR1 binding. ECM–FGF2 complexes promote Cyclin D1 induction that prevents G1 arrest even in the presence of antiestrogens. This work demonstrates that the ECM can drive ER signaling and resistance to endocrine therapy, and suggests that patients with ER+ breast cancer that have high mammographic breast density may benefit from existing FGFR-targeted therapies.Implications: This work uncovers how the ECM may mediate signaling between growth factors and ER+ breast cancer cells to promote estrogen-independent ER signaling and resistance to endocrine therapy.

3 April 2023
Verified
Other
Open access
JDJosh W. DiGiacomo
Josh W. DiGiacomo
Ines GodetInes Godet
Ines Godet
MTMichael Trautmann-Rodriguez
Michael Trautmann-Rodriguez
DGDaniele M. Gilkes
Daniele M. Gilkes
The extracellular matrix (ECM) is often unaccounted for in studies that consider the stromal contribution to cancer cell signaling and response to treatment. To investigate the influence of a fibrotic microenvironment, we use fibroblast-derived ECM scaffolds as a cell culture platform. We uncover that estrogen receptor–positive (ER+) breast cancer cells cultured within ECM-scaffolds have an increase in ER signaling that occurs via an MAPK-dependent, but estrogen-independent manner. The ECM acts as a reservoir by binding, enriching, and presenting growth factors to adjacent epithelial cells. We identified FGF2 as a specific ECM-bound factor that drives ER signaling. ER+ cells cultured on ECM matrices have reduced sensitivity to ER-targeted therapies. The sensitivity to ER-targeted therapy can be restored by inhibiting FGF2–FGFR1 binding. ECM–FGF2 complexes promote Cyclin D1 induction that prevents G1 arrest even in the presence of antiestrogens. This work demonstrates that the ECM can drive ER signaling and resistance to endocrine therapy, and suggests that patients with ER+ breast cancer that have high mammographic breast density may benefit from existing FGFR-targeted therapies.Implications:This work uncovers how the ECM may mediate signaling between growth factors and ER+ breast cancer cells to promote estrogen-independent ER signaling and resistance to endocrine therapy.

3 April 2023
Verified
Other
Open access
JDJosh W. DiGiacomo
Josh W. DiGiacomo
Ines GodetInes Godet
Ines Godet
MTMichael Trautmann-Rodriguez
Michael Trautmann-Rodriguez
DGDaniele M. Gilkes
Daniele M. Gilkes


3 April 2023
Verified
Other
Open access
JDJosh W. DiGiacomo
Josh W. DiGiacomo
Ines GodetInes Godet
Ines Godet
MTMichael Trautmann-Rodriguez
Michael Trautmann-Rodriguez
DGDaniele M. Gilkes
Daniele M. Gilkes
Figure S1. RNA sequencing of MCF7 cells cultured in ECM scaffolds indicate activation of estrogen response signatures. Figure S2. ER+ cell lines cultured in ECM scaffolds activate estrogen-responsive genes. Figure S3. ER+ cell lines cultured in ECM scaffolds enhance Erk phosphorylation. Figure S4. FGF2 activates the estrogen-like response of ER+ cells cultured in ECM scaffolds. Figure S5. Heatmap visualization on gene expression of Hallmark estrogen response early genes from biopsies of extratumoral regions of breast cancer patients with annotation of high or low mammographic breast density (=25%). Figure S6. Culturing of ER+ breast cancer cells in ECM scaffolds reduces sensitivity to endocrine therapies through ECM-FGF2. Figure S7. Proliferation and cell cycle analyses of MCF7 cells cultured in ECM scaffolds indicates reduction of arrest caused by endocrine therapy.